Literature DB >> 25083812

Evaluation of glycosaminoglycans and heparanase in placentas of women with preeclampsia.

Eduardo Augusto Brosco Famá1, Renan Salvioni Souza2, Carina Mucciolo Melo3, Luciano Melo Pompei4, Maria Aparecida Silva Pinhal5.   

Abstract

BACKGROUND: Preeclampsia is a multisystem disorder whose etiology remains unclear. It is already known that circulation of soluble fms-like tyrosine kinase-1 (sFlt-1) is directly involved in pre-eclampsia development. However, the molecular mechanisms involved with sFlt-1 shedding are still unidentified. We identified, quantified glycosaminoglycans and determined the enzymatic activity of heparanase in placentas of women with preeclampsia, in order to possibly explain if these compounds could be related to cellular processes involved with preeclampsia.
METHODS: A total of 45 samples collected from placentas, 15 samples from placentas of preeclampsia women and 30 samples from non-affected women. Heparan sulfate and dermatan sulfate were identified and quantified by agarose gel electrophoresis, whilst hyaluronic acid was quantified by an ELISA like assay. Heparanase activity was determined using biotynilated heparan sulfate as substrate.
RESULTS: The results showed that dermatan sulfate (P=0.019), heparan sulfate levels (P=0.015) and heparanase activity (P=0.006) in preeclampsia were significantly higher than in the control group. There was no significant difference between the groups for hyaluronic acid expression in placentas (P=0.110). The present study is the first to demonstrate directly the increase of heparan sulfate in human placentas from patients with preeclampsia, suggesting that endogenous heparan sulfate could be involved in the release of sFlt-1 from placenta, increasing the level of circulating sFlt-1.
CONCLUSION: Alterations of extracellular matrix components in placentas with preeclampsia raise the possibility that heparan sulfate released by heparanase is involved in mechanisms of preeclampsia development. Published by Elsevier B.V.

Entities:  

Keywords:  Dermatan sulfate; Heparan sulfate; Heparanase; Hyaluronic acid; Preeclampsia

Mesh:

Substances:

Year:  2014        PMID: 25083812     DOI: 10.1016/j.cca.2014.07.023

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  5 in total

1.  Heparanase regulation of sFLT-1 release in trophoblasts in vitro.

Authors:  Adrian C Eddy; Heather Chapman; Eric M George
Journal:  Placenta       Date:  2019-07-09       Impact factor: 3.481

2.  Syncytialization alters the extracellular matrix and barrier function of placental trophoblasts.

Authors:  Kyle H Moore; Haley A Murphy; Heather Chapman; Eric M George
Journal:  Am J Physiol Cell Physiol       Date:  2021-08-18       Impact factor: 5.282

3.  Heparanase modulation by Wingless/INT (Wnt).

Authors:  Carina Mucciolo Melo; Helena Bonciani Nader; Giselle Zenker Justo; Maria Aparecida Silva Pinhal
Journal:  Mol Biol Rep       Date:  2021-04-23       Impact factor: 2.316

4.  Hyaluronic Acid in Vascular and Immune Homeostasis during Normal Pregnancy and Preeclampsia.

Authors:  M M Ziganshina; S V Pavlovich; N V Bovin; G T Sukhikh
Journal:  Acta Naturae       Date:  2016 Jul-Sep       Impact factor: 1.845

5.  Integrated Proteomic and Metabolomic prediction of Term Preeclampsia.

Authors:  Ray Bahado-Singh; Liona C Poon; Ali Yilmaz; Argyro Syngelaki; Onur Turkoglu; Praveen Kumar; Joseph Kirma; Matthew Allos; Veronica Accurti; Jiansheng Li; Peng Zhao; Stewart F Graham; David R Cool; Kypros Nicolaides
Journal:  Sci Rep       Date:  2017-11-23       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.